- Home
- OBE vs LXRX Comparison
OBE vs LXRX Comparison
Compare OBE & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OBE | LXRX |
|---|---|---|
| Founded | 1979 | 1995 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 865.4M | 996.7M |
| IPO Year | 2005 | 2000 |
Fundamental Metrics
Financial Performance| Metric | OBE | LXRX |
|---|---|---|
| Price | $10.67 | $1.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $10.00 | $4.15 |
| AVG Volume (30 Days) | 792.0K | ★ 2.4M |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $49,803,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.21 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $5.44 | $1.10 |
| 52 Week High | $14.59 | $2.68 |
Technical Indicators
Market Signals| Indicator | OBE | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.12 | 31.10 |
| Support Level | $9.18 | $1.50 |
| Resistance Level | $10.92 | $1.81 |
| Average True Range (ATR) | 0.63 | 0.11 |
| MACD | -0.24 | -0.02 |
| Stochastic Oscillator | 7.57 | 4.12 |
Price Performance
Historical ComparisonAbout OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Sale of Oil.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.